{"name":"Amicus Therapeutics","slug":"amicus","ticker":"FOLD","exchange":"NASDAQ","domain":"amicusrx.com","description":"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, ","hq":"Philadelphia, PA","founded":0,"employees":"511","ceo":"","sector":"Rare Disease / Lysosomal","stockPrice":14.49,"stockChange":0,"stockChangePercent":0,"marketCap":"$4.5B","metrics":{"revenue":634209984,"revenueGrowth":23.7,"grossMargin":88.5,"rdSpend":0,"netIncome":-27110000,"cash":293536000,"dividendYield":0,"peRatio":17.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"agalsidase","genericName":"agalsidase","slug":"agalsidase","indication":"Fabry's disease","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pombiliti","genericName":"CIPAGLUCOSIDASE ALFA","slug":"cipaglucosidase-alfa","indication":"Late-onset Pompe disease","status":"marketed"}]}],"pipeline":[{"name":"agalsidase","genericName":"agalsidase","slug":"agalsidase","phase":"marketed","mechanism":"Biologic","indications":["Fabry's disease"],"catalyst":""},{"name":"Pombiliti","genericName":"CIPAGLUCOSIDASE ALFA","slug":"cipaglucosidase-alfa","phase":"marketed","mechanism":"Pombiliti works by replacing the deficient acid alpha-glucosidase enzyme in patients with Late-onset Pompe disease.","indications":["Late-onset Pompe disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":634210000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":634210000},{"period":"2024-12-31","value":528295000},{"period":"2023-12-31","value":399356000},{"period":"2022-12-31","value":329233000}],"grossProfit":561281000,"grossProfitHistory":[{"period":"2025-12-31","value":561281000},{"period":"2024-12-31","value":475352000},{"period":"2023-12-31","value":362030000},{"period":"2022-12-31","value":290634000}],"rdSpend":135843000,"rdSpendHistory":[{"period":"2025-12-31","value":135843000},{"period":"2024-12-31","value":109362000},{"period":"2023-12-31","value":152381000},{"period":"2022-12-31","value":276677000}],"sgaSpend":383487000,"operatingIncome":34491000,"operatingIncomeHistory":[{"period":"2025-12-31","value":34491000},{"period":"2024-12-31","value":34064000},{"period":"2023-12-31","value":-73494000},{"period":"2022-12-31","value":-204426000}],"netIncome":-27110000,"netIncomeHistory":[{"period":"2025-12-31","value":-27110000},{"period":"2024-12-31","value":-56106000},{"period":"2023-12-31","value":-151584000},{"period":"2022-12-31","value":-236568000}],"eps":-0.18,"epsHistory":[{"period":"2024-12-31","value":-0.18},{"period":"2023-12-31","value":-0.51},{"period":"2022-12-31","value":-0.82},{"period":"2021-12-31","value":-0.92}],"cash":214010000,"cashHistory":[{"period":"2025-12-31","value":214010000},{"period":"2024-12-31","value":213752000},{"period":"2023-12-31","value":246994000},{"period":"2022-12-31","value":148813000}],"totalAssets":949870000,"totalLiabilities":675629000,"totalDebt":442363000,"equity":274241000,"operatingCashflow":33145000,"operatingCashflowHistory":[{"period":"2025-12-31","value":33145000},{"period":"2024-12-31","value":-33891000},{"period":"2023-12-31","value":-69091000},{"period":"2022-12-31","value":-166575000}],"capex":-3296000,"capexHistory":[{"period":"2025-12-31","value":-3296000},{"period":"2024-12-31","value":-3553000},{"period":"2023-12-31","value":-7440000},{"period":"2022-12-31","value":-3766000}],"freeCashflow":29849000,"dividendsPaid":null,"buybacks":null,"employees":511,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":117081000,"ebit":14571000,"ebitda":16468000,"period":"2025-12-31","revenue":185212000,"epsBasic":null,"netIncome":1690000,"rdExpense":23741000,"epsDiluted":null,"grossProfit":158665000,"operatingIncome":15946000},{"sga":90036000,"ebit":45985000,"ebitda":47859000,"period":"2025-09-30","revenue":169061000,"epsBasic":0.06,"netIncome":17306000,"rdExpense":23415000,"epsDiluted":0.06,"grossProfit":149594000,"operatingIncome":34269000},{"sga":84543000,"ebit":-7616000,"ebitda":-5764000,"period":"2025-06-30","revenue":154688000,"epsBasic":-0.08,"netIncome":-24420000,"rdExpense":60848000,"epsDiluted":-0.08,"grossProfit":139471000,"operatingIncome":-7772000},{"sga":91827000,"ebit":-6590000,"ebitda":-4753000,"period":"2025-03-31","revenue":125249000,"epsBasic":-0.07,"netIncome":-21686000,"rdExpense":27839000,"epsDiluted":-0.07,"grossProfit":113551000,"operatingIncome":-7952000},{"sga":86668000,"ebit":19892000,"ebitda":21933000,"period":"2024-12-31","revenue":149706000,"epsBasic":null,"netIncome":14739000,"rdExpense":30190000,"epsDiluted":null,"grossProfit":134870000,"operatingIncome":15971000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.02,"netIncome":null,"rdExpense":null,"epsDiluted":-0.02,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.49,"previousClose":0,"fiftyTwoWeekHigh":14.5,"fiftyTwoWeekLow":5.51,"fiftyTwoWeekRange":"","fiftyDayAverage":14.4,"twoHundredDayAverage":10.88,"beta":0.48,"enterpriseValue":4698697216,"forwardPE":17.7,"priceToBook":16.43,"priceToSales":7.17,"enterpriseToRevenue":7.41,"enterpriseToEbitda":112,"pegRatio":0,"ebitda":41951000,"ebitdaMargin":6.6,"freeCashflow":47844500,"operatingCashflow":33145000,"totalDebt":442363008,"debtToEquity":161.3,"currentRatio":2.84,"returnOnAssets":2.5,"returnOnEquity":-11.6,"analystRating":"","recommendationKey":"hold","numberOfAnalysts":5,"targetMeanPrice":14.5,"targetHighPrice":14.5,"targetLowPrice":14.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.7,"institutionHeldPercent":104.4,"sharesOutstanding":314000712,"floatShares":311435326,"sharesShort":21923629,"shortRatio":6.36,"shortPercentOfFloat":7,"epsTrailing":-0.09,"epsForward":0,"revenuePerShare":2.06,"bookValue":0.88,"officers":[{"age":49,"name":"Mr. Bradley L. Campbell M.B.A.","title":"CEO, President & Director"},{"age":65,"name":"Mr. Simon Nicolas Reade Harford","title":"Chief Financial Officer"},{"age":61,"name":"Ms. Ellen S. Rosenberg J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":49,"name":"Mr. David M. Clark","title":"Chief People Officer"},{"age":53,"name":"Dr. Jeffrey P. Castelli Ph.D.","title":"Chief Development Officer"},{"age":46,"name":"Ms. Samantha L. Prout","title":"Chief Accounting Officer & Controller"},{"age":null,"name":"Dr. Jill  Weimer Ph.D.","title":"Chief Science Officer"},{"age":null,"name":"Mr. Andrew  Faughnan","title":"Vice President of Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://amicusrx.com","phone":"609 662 2000"}}